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ABSTRACT 
 
The transcription factor Nuclear factor of activated T cells c1 (NFATc1) is 
a master regulator of osteoclastogenesis.  Previous knockout studies have 
shown that global NFATc1 deletion in younger mice leads to poor 
osteoclastogenesis and osteopetrosis.  Here we show that the cathepsin k-cre 
mediated deletion of NFATc1 in mature osteoclasts leads to a phenotype with 
notable differences including the presence of abnormally large, multinucleate, 
TRAP-positive osteoclasts and the effacement of the bone marrow by stromal 
cells resembling a fibrotic reaction.  We characterize this phenotype in a 
multitude of ways. We show that the fibrosis phenotype: (1) presents between 
age E15.5 and P5, (2) is dependent on the presence of osteoclasts and is 
downstream of RANK, the cell surface receptor that triggers osteoclast 
differentiation (3) and is not likely an osteoblast lineage-intrinsic phenotype.  We 
hypothesized that NFATc1 in osteoclasts negatively regulates a secreted stromal 
lineage proliferative factor that functions in coupling.  Our in-vitro assays using 
media conditioned by cultured wild-type or knockout osteoclasts were unable to 
 v 
show differences in neither BMSC proliferation nor differentiation.  Last, we 
identify genes that are highly upregulated in NFATc1 knock-out osteoclasts and 
describe those that may function in regulation of stromal-lineage differentiation or 
proliferation.
 vi 
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INTRODUCTION 
 The diversity and importance of bone functions are often overlooked.  A 
major function of the skeletal system is to provide support for weight-bearing 
motor activity.  Microscopic damage accrues as a result of physical activity, and 
is repaired by constant cycling of phases of bone degradation and bone 
formation (T.  Negishi-Koga and Takayanagi 2009).  This process is referred to 
as bone remodeling.  Bone is, consequently, a very dynamic organ that 
continuously renews, replacing itself every 7-10 years (Sims and Gooi 2008).  
Additionally, bone houses and supports hematopoietic stem cells, is essential in 
regulating calcium homeostasis (Harada and Rodan 2003), and has been 
recently discovered to act as an endocrine organ regulating energy metabolism 
(Wagner and Karsenty 2001).   
 The delicate balance between bone resorption and bone formation is 
intricately regulated via a combination of chemokines, hormones, and 
biomechanical stimuli (T.  Negishi-Koga and Takayanagi 2009).  While these 
factors play differential roles throughout different parts of the skeletal system, it is 
ultimately the osteoclasts and the osteoblasts (and their precursors) that respond 
to these signals.  The interplay between the osteoblast—the bone forming cells—
and the osteoclasts—the bone resorbing cells—in their relative quantities and 
activities is what dictates the net effect on bone.  A shift in this equilibrium 
determines whether the bone is in a bone forming or bone resorbing state.   
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The Three Cell Types of Bone – Osteoclasts, Osteoblasts and Osteocytes 
The osteoclast is an incredibly specialized and unique cell.  It is the only 
cell type capable of resorbing large quantities of bone.  Its bone destructive 
properties make it the antithesis to the osteoblast.  Osteoclasts are of 
hematopoietic origin and form through the fusion of mononuclear myeloid 
precursors (Boyle, Simonet, and Lacey 2003).  Fusion and differentiation 
ultimately results in a multinucleated giant cell, a distinct feature on its own.  
These giant mature osteoclasts, in the process of differentiation, express specific 
machinery for the resorption of bone including the ability  to actively secrete 
hydrochloric acid, cathepsin K and matrix metalloproteinases (MMPs), which 
synergize to degrade the bone matrix (Boyle, Simonet, and Lacey 2003).   
The maturation of osteoclasts from their precursors is dependent on 
factors secreted by the osteoblast-lineage cells: macrophage colony-stimulating 
factor (M-CSF) and receptor activator of nuclear factor kβ ligand (RANKL) (T.  
Negishi-Koga and Takayanagi 2009).  M-CSF interaction with its receptor on the 
myeloid precursor commits the cell to become an osteoclast precursor (Edwards 
and Mundy 2011), causing the upregulation of receptor activator of nuclear factor 
kβ (RANK) (Figure 1).  Subsequent interaction of RANKL with RANK recruits a 
variety of regulators that will cause the eventual transcriptional upregulation of 
nuclear factor of activated T cells cytoplasmic 1 (NFATc1) (Edwards and Mundy 
2011; Aliprantis et al. 2008) 
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NFATc1 is considered to be the master regulator of osteoclastogenesis.  It 
is the most upregulated transcription factor induced by RANKL (Takayanagi et al.  
2002) which reiterates the importance of this transcription factor for 
osteoclastogenesis.  NFATc1 is part of a family of nuclear transcription factors 
that are, with the exception of NFAT5, regulated by calcineurin—a 
serine/threonine phosphatase activated by increasing intracellular calcium ions 
(T.  Negishi-Koga and Takayanagi 2009).  Upon RANKL stimulation, NFATc1 is 
dephosphorylated by calcineurin, exposing a nuclear localization (Takayanagi et 
al.  2002).  NFATc1 then translocates into the nucleus where it cooperates with 
other transcription factors to activate osteoclast specific genes.  Among these 
genes are: 1. dendritic cell-specific transmembrane protein (DC-STAMP) and the  
vacuolar proton pump subunit Atp6v0d2, which are necessary for fusion, 2. 
cathepsin K (CtsK), a protease secreted during resorption, and 3. β3 integrin, a 
molecule necessary for the binding and formation of the resorption lacunae 
(Kuroda et al.  2012).  These genes, however, only represent a small proportion 
of genes that are targeted by NFATc1 regulation (Charles et al. 2012).   
Loss of NFATc1 results in embryonic lethality (De la Pompa et al.  1998).  
Other methods have been employed to study the effects of NFATc1 deficiency 
and have demonstrated in-vivo that NFATc1 is essential in osteoclastogenesis 
(Winslow et al.  2006).  Inducible knockouts of NFATc1 resulted in mice that 
exhibited severe osteopetrosis and a severe lack of tartrate-resistant acid 
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phosphatase-positive (TRAP-positive) multinucleated cells (Aliprantis et al.  
2008).   
 
Figure 1: Osteoclast Differentiation.  Binding of RANKL and M-CSF to 
respective receptors on the osteoclast activates NFATc1 transcription and 
activation to support osteoclast differentiation (Figure taken from Edwards and 
Mundy 2011, fig.  2) 
 
 Osteoblasts—the bone forming cells—are responsible for secreting the 
collagenous bone matrix and its subsequent mineralization.  Osteoblasts are thus 
key mediators of bone mass (Zelzer and Olsen 2003).  Osteoblasts arise from 
mesenchymal progenitors.  The transition from mesenchymal stem cell to mature 
osteoblast is dependent on, the transcriptional control of runt-related 
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transcriptional factor 2 (Runx2) and downstream Osterix (Osx).  Knock-out 
experiments have demonstrated that Runx2 is an early transcriptional regulator 
in osteoblast differentiation (Figure 2).  Ablation of Runx2 resulted in a complete 
absence of osteoblasts (Kim et al.  1999).  Osterix, downstream of Runx2, is 
responsible for the transition from pre-osteoblast to immature osteoblasts (Marie 
2008).  Anything affecting this transition compromises the ability of the osteoblast 
to lay down bone matrix, resulting in abnormal bone. 
 
Figure 2: Mesenchymal Differentiation into Bone Cells.  Differentiation from 
mesenchymal cells into osteoprogenitor cells depends on the transcription factor 
Runx2.  Further differentiation into osteoblasts requires the transcriptional 
regulator Osx (Figure Amended from Marie 2008, fig.  1).   
 
Osteoblasts embedded in the mineralized bone matrix are subject to yet 
another level of differentiation, giving rise to another participant in bone 
remodeling—the osteocyte.  As the osteoblast becomes entrapped in the 
osteoid, the osteoblast  develops dendritic processes that extend throughout the 
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bone.  These dendritic processes help the osteocyte fulfill its roles in regulating 
both mineralization and resorption (Bonewald 2011) by communication with the 
osteoblasts and osteoclasts.   
The Bone Remodeling Cycle 
Bone remodeling is thought to occur in discrete phases: initiation, 
transition, and termination (K.  Matsuo and Irie 2008).  Bone resorption begins 
with initiation which is demarcated by the recruitment of osteoclast precursors 
(OCPs) and the activation and differentiation of these precursors.  Once 
resorption has occurred, the bone environment must switch to forming new bone 
instead of resorbing it—a phase that is known as transition.  During this transition 
phase, the osteoclasts are believed to undergo apoptosis while osteoblast 
precursors are recruited, proliferated, and differentiated.  Once the bone 
environment equilibrates to a state of bone formation where the mature 
osteoblasts are actively forming new bone, the bone remodeling process is said 
to be in its termination phase(K.  Matsuo and Irie 2008).  As one would imagine, 
the orchestration of these phases requires highly intricate communication 
between the bone cells, particularly the osteoblasts and osteoclasts.  
Bone remodeling relies on the coupling of bone resorption and bone 
formation.  An integral part of this coupling phenomenon is the intercellular 
communication between osteoblasts, osteocytes and osteoclast lineages.  Each 
population must signal the other at every step in the remodeling process in order 
to coordinate the transitions between formation and resorption.  This 
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communication can be achieved by several means including secretion of 
cytokines or paracrine factors, cell-cell contact, and local factors released from 
the turnover of the bone matrix (N.  A.  Sims and Walsh 2012).  Examples of 
each of these modes of communication are discussed below. 
Paracrine Factors.  Several aspects of paracrine communication 
between the osteoblasts and osteoclasts have been well studied.  Among the 
most studied are the factors produced by osteoblast lineage cells that signal for 
the initiation of bone remodeling: RANKL and M-CSF.  While it remains unclear 
what truly initiates bone remodeling, there is evidence implicating parathyroid 
hormone (PTH), extracellular calcium levels, and/or mechanical stress (Tatsumi 
et al.  2007) as possible initiators.  Osteoblast lineage cells regulate 
osteoclastogenesis via the production of RANKL and M-CSF (Lacey et al. 1998; 
Lagasse and Weissman 1997)steoclast progenitors (OCPs) express receptors 
for RANKL and M-CSF on the surface of their membrane—RANKand M-CSF 
Receptor (c-fms) respectively.  RANKL drives the proliferation and fusion of the 
OCPs in the bone marrow to form mature osteoclasts (Boyce and Xing 2008).  
M-CSF is also necessary but insufficient by itself to induce the differentiation of 
the osteoclast precursors into osteoclasts (Yoshida et al.  1990).  M-CSF 
appears to be essential for the survival and proliferation of the OCPs (T. Negishi-
Koga and Takayanagi 2009).  Deletion of M-CSF and/or RANKL expression in 
osteoblasts resulted in the loss of mature osteoclasts and a osteopetrosis 
phenotype (Yoshida et al.  1990; N.  A.  Sims and Walsh 2012). Furthermore, 
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specific deletion of RANKL in osteocytes is sufficient to cause osteopetrosis 
(Nakashima et al. 2011). These two factors together are critical in inducing the 
correct profile of genes needed to form mature osteoclasts (Boyle, Simonet, and 
Lacey 2003).   
The RANK/RANKL system has been extensively studied.  RANKL is a 
homotrimeric protein that is membrane bound and secreted after being cleaved 
by matrix metalloproteases (MMP3 or 7) or a disintegrin and metalloprotease 
domain (ADAM) (B. F. Boyce and Xing 2008).  Both RANKL and RANK are 
members of the tumor necrosis factor (TNF) receptor superfamily (Boyle, 
Simonet, and Lacey 2003).  Ablation of either RANKL expression or RANK 
results in an identical phenotype, osteoclast deficient osteopetrosis (Li et al.  
2000), emphasizing the importance of this ligand-receptor interaction in bone 
remodeling.  Another member of the TNF-receptor superfamily is 
Osteoprotegerin (OPG).  OPG is a soluble decoy receptor for RANKL secreted 
by osteoblasts.  OPG competes with RANK in binding to RANKL and, 
consequently, inhibits osteoclast formation and activity (Boyle, Simonet, and 
Lacey 2003).  As expected, overexpression of OPG resulted in an osteoclast 
deficient osteopetrosis (Wagner and Karsenty 2001) and deletion of OPG 
resulted in a osteoclast rich osteoporosis (Simonet et al.  1997).  The severe 
phenotypes observed in these in vivo studies suggest that the 
RANK/RANKL/OPG axis is an extremely key regulator of bone remodeling and 
osteoclastogenesis. 
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Cell-cell signaling.  Bidirectional signaling between cell surface proteins 
is another mode of communication that plays a role in bone remodeling.  One 
example of such interaction in bone cells would be the cell surface Eph/ephrin 
system.  Cell-cell interactions via these ephrins and Eph appear to control the 
migration, proliferation, and differentiation of mesenchymal (Osteoblast 
precursor) and hematopoetic (Osteoclast precursor) stem cells (Koichi Matsuo 
and Otaki 2012).  Eph receptors are subcategorized as members of the receptor 
tyrosine kinase family and are activated by ephrin ligands (Pasquale 2008).  Both 
receptors and ligands can be further subcategorized into A and B groups and 
they are differentially expressed between the different bone cells and even within 
the same cell as bone remodeling progresses. 
The aforementioned initiation phase of bone formation consists of the 
recruitment, activation, and differentiation of Osteoclast precursors.  During early 
osteoclastogenesis, Osteoclast derived ephrinA2 is upregegulated.  Upon 
interaction with osteoblast EphA2, bidirectional signaling inhibits differentiation in 
osteoblasts while stimulating differentiation in osteoclasts (Koichi Matsuo and 
Otaki 2012).  This specific example demonstrates how bone cells communicate 
directly during initiation.  Interestingly, RT-PCR profiles of these osteoclasts 
reveal that the expression of ephrinA2 decreases as they continue in culture in 
RANKL and M-CSF (Irie et al.  2009).  This finding further reiterates that the bone 
cells maintain constant communication throughout the entire remodeling process.   
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The Eph/ephrin system is also at work as the initiation phase draws to an 
end.  Bidirectional signaling, specifically between osteoclast ephrinB2 and 
osteoblast EphB4, appears to be a negative regulator of resorption (Figure 3).  
Reverse signaling into osteoclasts simulated by the addition of EphB4-Fc to 
osteoclast cultures resulted in the inhibition of osteoclast differentiation and 
activity(Koichi Matsuo and Otaki 2012).  Forward signaling of EphB4 into 
osteoblasts appeared to promote osteoblast differentiation (Koichi Matsuo and 
Otaki 2012).  The interaction of ephrinB2 and EphB4 in this later stage of 
initiation helps the bone progress into the transition phase of bone remodeling.   
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Figure 3: Osteoclast and Osteoblast bi-directional signaling via Eph/ephrin 
system.  Bi-directional communication between the osteoblasts and osteoclasts 
via the Eph/ephrin system plays a regulatory role in bone coupling.  Upregulation 
in ephrinA2 in early osteoclasts and interaction with EphA2 in osteoblasts 
positively regulates osteoclast differentiation while inhibiting osteoblast 
differentiation, thereby attenuating bone formation and augmenting bone 
resorption.  As osteoclasts differentiate, expression of ephrinA2 decreases while 
ephrinB1 increases.  Subsequent interaction of ephrinB1 with EphB4 on 
osteoblasts inhibits osteoclast differentiation while stimulating differentiation in 
osteoblasts (Figure Adapted from Koichi Matsuo and Otaki 2012, fig.  3) 
  
 More recently, the cell-cell interactions of Semaphorins and Plexins have 
also been implicated as coupling factors that contribute to the transition phase of 
bone remodeling.  RANKL appears to induce the expression of Semaphorin-4D 
(Sema4D) on osteoclasts during osteoclastogenesis (Takako Negishi-Koga et al.  
2011).  Sema4D is expressed exclusively on osteoclasts (Kang and Kumanogoh 
2013) and interacts with Plexin-B1 receptor on the osteoblast membrane.  Loss-
of-function studies revealed that this specific cell-cell interaction played an 
important role in the suppression of bone formation.  Loss of either Sema4D or 
Plexin-B1 resulted in increased bone mass, osteoblast surface, and bone 
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formation rates (Takako Negishi-Koga et al.  2011).  It is believed that the 
Sema4D-PlexinB1 interaction has an inhibitory effect on mineralization of 
osteoblasts while having a stimulatory effect on osteoclast formation (Takako 
Negishi-Koga et al.  2011).  This direct form of communication is one of the many 
ways the bone cells harmoniously interact to ensure proper bone remodeling. 
Factors released from the bone matrix.  During the transition phase of 
bone remodeling, osteoblast precursors need to be recruited and stimulated to 
differentiate.  One initial hypothesis was that the osteoclasts direct the next steps 
by liberating coupling factors trapped in the bone matrix with their resorptive 
activity.  Factors such as insulin-like growth factor (IGF) I and II and 
Transforming Growth Factor (TGF)-β are potential factors.  Supporting this 
hypothesis, active TGF-β was shown to be released from the bone matrix by 
osteoclast resorption, and to be required for mesenchymal stem cell migration to 
trabecular surfaces in vivo (Tang et al.  2009).  In contrast, others have found 
that the activity of these osteoclasts was dispensable for the activation of 
osteoblastic bone formation (K.  Matsuo and Irie 2008)..  Knocking out osteoclast 
formation altogether via c-fos knockout resulted in reduced bone resorption as 
well as bone formation in mice, suggesting the presence of coupling (Grigoriadis 
et al.  1994).  Targeted elimination of osteoclast activity without affecting 
osteoclast numbers via deletion of c-src or chloride-7 channel resulted in the 
inhibition of bone resorption while leaving bone formation unaffected (Brockstedt 
et al.  1996).  These findings suggest that osteoclast secrete factors that recruit 
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osteoblast precursors and/or promotes differentiation, thus stimulating bone 
formation.   
An osteoclast derived coupling factor.  The notion that bone resorption 
must be tightly coupled to bone formation during transition denotes an 
increasingly important role for osteoclast to osteoblast communication during 
resorption.  Osteoclasts must be able to communicate to the osteoblasts that 
resorption is complete and poise the mesenchymal cells for a subsequent phase 
of bone formation.  One compelling hypothesis postulates the secretion of a 
“coupling factor” from the osteoclast.  This coupling factor should, inferring from 
what must occur in the transition phase, have functions in any one or 
combination of the following: to recruit mesenchymal osteoblast progenitors, to 
stimulate the proliferation of these progenitors, or to activate the progenitors to 
become bone forming osteoblasts.  Although some coupling mechanisms have 
already been identified, the complexity in the regulation of bone turnover denotes 
a high likelihood that there are other potential coupling factors to be identified.  
We have already highlighted several notable forms of osteoclast-
osteoblast communication.  In these examples, the differentiation and activity of 
the osteoclast causes the upregulation of factors that regulated osteoblast 
activity.  Many of these factors, like the ephrins for example, are under the 
control of NFATc1.  These downstream genes of NFATc1 may function in 
coupling the activity of the osteoclast to the osteoblast.   
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Recent work in our lab provides support for an osteoclast derived factor 
promoting the proliferation of osteoblast lineage stromal cells.  Deletion of key 
osteoclast transcription factor NFATc1 in mature osteoclasts results in a 
disorganized and thickened skeleton, where bone marrow has been replaced 
with spindle shaped osteoblast lineage cells, almost obliterating normal 
hematopoietic elements.  In contrast to deletion of NFATc1 in osteoclast 
precursors, which is characterized by an osteoclast poor state, mice with deletion 
in NFATc1 in mature osteoclasts have numerous giant abnormal osteoclasts. 
Deletion of RANK in mature osteoclasts on the other hand results in mice with a 
classic osteoclast poor osteopetrosis without the abnormal bone marrow stromal 
hyperproliferation.  From these observations, we hypothesize that NFATc1 in 
mature osteoclasts negatively regulates an osteoblast lineage proliferative factor 
that functions in coupling.  In this thesis, we attempt to (1) characterize and 
define the stromal cell infiltrate in the marrows of mice deficient in NFATc1 in 
mature osteoclasts (using a cathepsin k-cre mediated deletion of a floxed Nfatc1 
allele, henceforth referred to as Nfatc1fl/∆ Ctsk-Cre+) and (2) identify this 
proliferative factor produced by Nfatc1fl/∆ Ctsk-Cre+ osteoclasts.  By elucidating 
the communication between osteoclasts and osteoblasts in bone coupling, we 
hope to illuminate novel players in bone regulation that may have a role in the 
pathogenesis of bone disease and that may serve as therapeutic targets to treat 
these diseases.   
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Methods 
Mice 
Nfatc1fl/fl mice were previously generated as described in Aliprantis 2008.  To 
generate mice lacking NFATc1 in mature osteoclasts, Nfatc1fl/fl mice
 were 
crossed to mice expressing Cre recombinase under the control of the Cathepsin 
K promoter, which is active in mature osteoclasts.  These Ctsk-Cre mice were a 
gift of Dr.  Shigeaki Kato (Ref: Cell, 2007 130:811-23).  Sporadic deletion of the 
floxed Nfatc1 allele in the maternal line resulted in the generation of the Nfatc1 
in some cases, such that the genotype of mutant mice could be either Nfatc1fl/fl 
CtskCre+ or Nfatc1fl/ CtskCre+.  Genotyping was performed by PCR using the 
following primers to detect wild type, floxed and deleted alleles of Nfatc1, and the 
presence of Ctsk-Cre: Nfatc1 (AAGGAATTACTGGGAAGCCTGGCA, 
AGGGACTATCATTTGGCAGGGACA, ACAGGAAACAGCTCTGTTCCACAC) 
CreF (GCGGTCTGGCAGTAAAAACTATC), CreR 
(GTGAAACAGCATTGCTGTCACTT).  CD45.1 mice were purchased from 
Jackson.  For chimera experiments, mice were irradiated (800 RAD), allowed to 
rest for 4 hours, followed by tail vein injection of CD45.2 donor fetal liver cells.  
Irradiated mice were maintained on sulfatrim to prevent infection.  All animal 
experimentation was performed in accordance with the Association for 
Assessment and Accreditation of Laboratory Animal Care and approved by 
Standing Committee on Animals at Harvard. 
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In-Vitro Culture of Murine Osteoclasts 
Osteoclasts were cultured from hematopoetic progenitors found in bone marrow, 
spleen, or fetal livers.  Bone marrow cells were isolated from long bones by 
vigorously flushing the marrow with Hanks buffered salt solution (HBSS).  
Splenocytes were prepared by crushing dissected spleens through a 70µm 
strainer followed by washing the filter with HBSS.  Fetal livers were isolated from 
E13.5 and E15.5 fetuses and cell suspensions were prepared as with spleens 
(see below for additional details).  The samples were pelleted by centrifugation at 
1000rpm for 6-8 minutes.  With spleen and bone marrow samples, red blood cell 
(RBC) lysis was performed using a hypotonic lysis buffer and cells were 
resuspended in complete α-MEM media (alpha-minimal essential media (GIBCO) 
supplemented with penicillin/streptomycin, 10% Fetal Bovine Serum (Hyclone)) 
containing either 10% CMG14-12 conditioned-medium (CMG)  or 40ng/mL 
recombinant M-CSF (R&D) to drive myeloid cell expansion.  Cells were plated 
onto suspension culture dishes (Corning Costar Ins) that stromal and lymphoid 
cells do not adhere to and expanded for three days.  For osteoclast 
differentiation, expanded cells were lifted using either 10mM EDTA in phosphate 
buffered saline or non-enzymatic dissociation buffer (GIBCO).  Cells were 
resuspended in osteoclast media (complete α-MEM containing 5ng/mL RANKL 
(R&D) and either 20ng/mL MCSF or 5% CMG supernatant.) and plated at density 
of 2x104/cm2.  Media was replaced on day 3 and 5.   
 In order to assess osteoclast formation, cultures were fixed in 4% 
paraformaldehyde for 10 minutes, washed, and stained for tartrate resistant acid 
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phosphatase (TRAP) activity using standard methods (ref Bone Research 
Protocols, Miep H.  Helfrich and Stuart H.  Ralston, 2003, Humana Press, pp 67-
68.) 
 
Fetal Liver Isolation 
E13.5 - E15.5 fetuses were isolated by caesarian-section of euthanized pregnant 
females.  Using a stereo microscope, fetal livers were carefully removed from the 
fetuses and placed into complete α-MEM media.  Fetal livers were homogenized 
by repeated pipetting and passed through a 70µm filter.  Samples were pelleted 
by centrifugation at 1000rpm for 6-8 minutes.  Fetal livers were then 
resuspended in freezing media (10% dimethylsulfoxide in HBSS) and stored 
overnight at -80⁰ C and later into liquid nitrogen.   
 
Generation of Osteoclast Conditioned Media 
Osteoclast conditioned media was generated by culturing expanded OCP from 
spleen, bone marrow or fetal livers, on 24 well plates in 0.5mL/well of either 
complete αMEM with 10% CMG and 5ng/mL RANKL or complete α-MEM with 
20ng/mL M-CSF or 5ng/mL RANKL.  At 3 and 5 days in this media fresh M-CSF 
and RANKL cytokines were added.  Media was collected after 7 days in culture.   
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Osteoblast Cultures 
Bone marrow stromal sells (BMSCs) were isolated from young pups, ages P5-
P10.  Whole hindlimbs and forelimbs were collected and pooled according to 
genotype.  Limbs were washed with 70% Ethanol, HBSS, and placed in sterile 
HBSS.  Limbs were then minced and digested in 1mg/mL collagenase II, and 
2mg/mL dispase in α-MEM media at 37˚C for approximately 40 minutes with 
agitation.  The enzymes were subsequently inactivated with an excess of FBS 
containing media.  The digested limbs were then passed through a 70µm strainer 
and centrifuged for 5-8 minutes at 1000rpm.  RBC lysis was optionally performed 
and cells were plated in BMSC media (α-MEM supplemented with 10% FBS, 
penicillin/streptomycin, L-glutamine and non-essential amino acids).  For 
proliferation assays, cells were plated at a density of 1-3x103/cm2, while for 
differentiation assays cells were plated at a density of 1-1.5x104/cm2. 
 
Osteoblast Proliferation Assays 
AlamarBlue (Invitrogen) indicator was used to quantify number of viable cells at a 
given time point and used according to the manufacturer’s instruction.  
Proliferation rates were determined by serial measurement of cell number over 
time.  Briefly, culture media was replaced with alamar blue diluted to working 
concentration in culture media.  Assays were incubated at 37˚C for 4 hours and 
fluorescence at 590nm with an excitation wavelength of 560nm was measured 
using a Synergy H1 fluorimeter (BioTek).   
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Osteoblast Differentiation Assays 
BMSCs are expanded to confluence in BMSC media and lifted using 1X Trypsin-
EDTA.  The BMSCs are then plated at a density of 1-1.5x104/cm2 in BMSC media 
and incubated at 37˚C to adhere.  BMSC media was replaced by osteoblast 
differentiation media (BMSC media with 50µg/mL ascorbic acid and 5mM beta-
glycerophosphate).  To limit the formation of osteoclasts from contaminating 
hematopoietic elements, OPG (100ng/mL) was also added to osteoblast 
differentiation media. 
 
Micro-computed tomography (µCT) 
Imaging of femurs was performed using a Scanco Medical µCT 35 system with a 
voxel size of 7µm.  Femurs were scanned in 70% ethanol using an X-ray 
potential, intensity, and integration time of 55kVp, 0.145mA and 600ms 
respectively, scanning the region from the distal femur to approximately 3mm 
proximal.  Differentiating trabecular from cortical bone employed a semi-
automated contouring approach, using a threshold of 352.3 mgHA/cm3 for 
marrow/trabecular bone cut-off.  3D reconstruction of the entire scan was done 
using the manufacturer supplied software.  Calculations for bone volume fraction 
(BV/TV) and trabecular thickness (Tb.Th) were performed on the region 0.28mm 
proximal to the growth plate and extending 2.1mm.   
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Histology 
Bones were fixed in freshly prepared 4% phosphate buffered formaldehyde 
(PBF) for 24 hours followed by decalcification in with 3-4 changes of 0.5M EDTA 
over 1 month.  The bones were then paraffin embedded and 10µm longitudinal 
sections were taken at the growth plate for H&E and TRAP staining.  TRAP 
staining on tissue sections was performed according to published methods 
(Erlebacher and Derynck 1996).   
 
Flow cytometry  
BMSC isolated as above were incubated with APC conjugated anti-mouse CD45 
antibody (Biolegend) at 4˚C for 20minutes, washed and CD45- cells were sorted 
by fluorescence activated cell sorting on a FACS Aria (BD).  For chimerism 
studies, bone marrow and spleen were isolated as usual, peripheral blood 
leukocytes (PBLs) were purified on a ficoll gradient, cells were stained with allele 
specific anti-bodies to CD45.1 and CD45.2 (Biolegend) and analyzed by flow 
cytometric cell analsyis on a FACS Canto (BD). 
 
Quantitative Real-Time PCR (qRT-PCR) 
 RNA was isolated using a RNeasy Mini Kit (Qiagen) according to 
manufacturer instructions.  cDNA was synthesized from the isolated RNA using a 
kit supplied by Applied Biosystems and a Veriti 96 Well Thermal Cylinder 
(Applied Biosystems) according to manufacturer instructions.  FAST SYBR 
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(Applied BIosystems) Green Master Mix was used in conjunction with a Step-
One Plus Real-Time PCR System (Applied Biosystems) to perform real-time 
quantitative PCR.  Average critical temperature (Ct) values were calculated from 
duplicate technical replicates.  Using the ∆Ct method, the quantity of mRNA was 
calculated relative to Hprt values.  The qRT-PCR primers used in our 
experiments are listed in Table 1. 
 
Table 1: qRT-PCR Primers used in this study. Asterisk denotes primer 
sequences obtained from PrimerBank (Wang and Seed 2003). 
Primer Set Forward Primers (5’-3’) Reverse Primers (5’-3’) 
Hprt GTTAAGCAGTACAGCCCCAAA AGGGCATATCCAACAACAAACTT 
RankL CAGCATCGCTCTGTTCCTGTA CTGCGTTTTCATGGAGTCTCA 
Tnalp CACAATATCAAGGATATCGACGTGA ACATCAGTTCTGTTCTTCGGGTACA 
Runx2 TACAACCATACCCAGTCCCTGTTT AGTGCTCTAACCACAGTCCATGCA  
Osx ATGGCGTCCTCTCTGCTTGA  GAAGGGTGGGTAGTCATTTG 
 
Ocn GGGCAATAAGGTAGTGAACAG 
 
GCAGCACAGGTCCTAAATAGT 
 
CalcR GCCTCCCCATTTACATCTGC 
 
CTCCTCGCCTTCGTTGTTG 
 
Nfatc1ex3* TGCCTTTTGCGAGCAGTATCT CAGGCAAGGATGGGCTCATAT 
Tgfb2* CTTCGACGTGACAGACGCT  GCAGGGGCAGTGTAAACTTATT  
Fgf13* CTCATCCGGCAAAAGAGACAA TTGGAGCCAAAGAGTTTGACC 
Inhbb* CTTCGTCTCTAATGAAGGCAACC  CTCCACCACATTCCACCTGTC 
 
Tnfrsf22* AAATGTCCCGCTGGTGAATAC GGCGGCACGATTCTGGAAA 
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Results 
1. Phenotype of mice lacking NFATc1 in mature osteoclasts.   
Genetic ablation of NFATc1 in mature osteoclasts driven by osteoclast 
specific promotor CathepsinK (Nfatc1fl/∆ Ctsk-Cre+) results in a distinct 
phenotype.  These mice are smaller compared to wild-type littermates— referred 
to as being “runted” (Figure 4A).  Similar to mutant mice lacking osteoclast 
activity, these Nfatc1fl/∆ Ctsk-Cre+ mice are toothless (Figure 4B).   
 
Figure 4: Gross Nfatc1fl/∆ CtsKCre+ Phenotype.  Photographs of a Postnatal 
Day 14 Nfatc1fl/∆ Ctsk-Cre+ mouse (seen on right in both A & B) and its wild-type 
littermate (seen on left in both A & B).  A.  Nfatc1fl/∆ Ctsk-Cre+ mice are runted 
compared to a wild-type littermate.  B.  Nfatc1fl/∆ Ctsk-Cre+ mice are toothless.   
 
Micro-computed tomography (µCT) imaging was performed on femurs isolated 
from Nfatc1fl/∆ Ctsk-Cre+ mice and a wild-type litter mate at post-natal day 14 
(P14) (Figure 5).  Imaging demonstrates decreased femur length, increase in 
trabeculae, a diminished or absent secondary center of ossification and an 
absence of cortical bone in mutants compared with wild-type.  Although short 
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femur length and increased trabecular bone are consistent with defective 
osteoclast number or function such as may be seen in Rankfl/fl Ctsk-Cre+ mice, 
defects in cortical bone and secondary center of ossification are unique to the 
Nfatc1fl/∆ Ctsk-Cre+ mutant. 
 
Figure 5: µCT Characterization of Nfatc1fl/∆ CtsK-Cre+ Phenotype.  µCT 
scans of femurs of P14 WT Mouse (left) and P14 Nfatc1fl/∆ Ctsk-Cre+ mouse 
(right, same magnification).  The femur length of the Nfatc1fl/∆ Ctsk-Cre+ mouse is 
significantly shorter than that of its wild-type littermate.  Furthermore, the 
Nfatc1fl/∆ Ctsk-Cre+ mouse shows increased trabecular bone when compared 
with its wild-type littermate. 
 
The histologic phenotype of Nfatc1fl/∆ Ctsk-Cre+ mice is also strikingly 
distinct from classic osteoclast-poor osteopetrosis.  H&E sections of Nfatc1fl/∆ 
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Ctsk-Cre+ femurs reveal that the marrow, normally inhabited by hematopoietic 
cells, is replaced by flat, spindle-shaped, fibroblast-like, stromal cells (Figure 6B, 
right)—a fibrotic phenotype that is not seen in other forms of osteoclast-poor 
osteopetrosis.  In comparison, deletion of Rank in mature osteoclasts (Rankfl/fl 
Ctsk-Cre+) results in a classic osteoclast-poor osteopetrosis, with increased 
trabeculae but normal hematopoietic elements present in the remaining bone 
marrow space (figure 6B), and absence of multinucleated osteoclasts (Figure 
6C).  Surprisingly, Nfatc1fl/∆ Ctsk-Cre+ mice have abnormal giant, multinucleate, 
TRAP-positive osteoclasts, which are not present in osteoclast-poor 
osteopetrosis, suggesting that NFATc1 expression in early osteoclastogenesis is 
sufficient for osteoclast formation. 
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Figure 6: The Nfatc1fl/∆ Ctsk-Cre+ phenotype is not a typical Osteoclast Poor 
Osteopetrosis.  A.  Femoral growth plate of, from right to left, wild-type, Nfatc1fl/∆ 
Ctsk-Cre+ knockout, Rankfl/fl Ctsk-Cre+ knockout.  H&E 5x.  B.  20x magnification 
of boxed regions in (A) reveals an abnormal, spindle shaped, stromal cell 
infiltrate instead of normal hematopoietic elements in the marrow in the in 
Nfatc1fl/∆ Ctsk-Cre+ marrow (left) while the in Rankfl/fl Ctsk-Cre+ (right) has normal 
appearing marrow.  C.  40x magnifications of TRAP positive osteoclast lineage 
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cells.  Nfatc1fl/∆ Ctsk-Cre+ (center) shows an example of a giant, multinucleated, 
TRAP-positive, abnormal osteoclast.   
  
 
To determine the exact age at which marrow fibrosis presents, we 
performed histopathologic analysis of the femurs and humeri, respectively, of 
younger mice at day 5 post-natal mice (P5) and day 16.5 embryos (E16.5).  The 
abnormal bone marrow stromal cell infiltrate was present in the P5 Nfatc1fl/∆ Ctsk-
Cre+ mice but not in the E16.5 Nfatc1fl/∆ Ctsk-Cre+ mice (Figure 7).  Histological 
analyses between these two ages will be performed in order to further pinpoint 
the age of onset. 
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Figure 7: Marrow Fibrosis Phenotype presents between Age E16.5 and P5.  
A.  Stromal infiltrate is present by P5.  WT (left) and Nfatc1fl/∆ Ctsk-Cre+ (right) 
femur, H&E, 20X.  B.  Nfatc1fl/∆ Ctsk-Cre+ marrow is indistinguishable from the 
WT littermate at E16.5.  .  WT (left) and Nfatc1fl/∆ Ctsk-Cre+ (right) humerus, H&E, 
20X 
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Marrow fibrosis has been described in both conditions of high bone 
turnover (Weinstein 2006) and in hematological diseases (Kuter et al.  2007).  
Silver staining of reticulin fibers is one way of distinguishing between the two 
types of fibrosis, where hematological diseases tend to be positive for these 
fibers (Kuter et al.  2007).  In order to further characterize the marrow fibrosis 
found in these Nfatc1fl/∆ Ctsk-Cre+ knockouts, we stained longitudinal sections of 
P14 femurs for silver binding reticulin fibers.  Our positive controls, liver and 
spleen sections, had darkly stained and well defined fibers.  The femurs in both 
wild-type and Nfatc1fl/∆ Ctsk-Cre+ mice, however, showed only a diffuse 
amorphous silver stain (Figure 8).  The lack of well defined, silver binding 
reticulin fibers suggests that the marrow fibrosis seen in Nfatc1fl/∆ Ctsk-Cre+ mice 
is associated with high bone turnover rather than hematologic disease. 
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Figure 8: Negative Reticulin Stain in Nfatc1fl/∆ Ctsk-Cre+ Marrow 
Characterizes Fibrosis as one of High Bone Turnover.  A.  Reticulin stain on 
liver shows discrete silver stained reticulin fibers.  B.  No discrete positively 
stained fibers are detected on p15 Nfatc1fl/∆ Ctsk-Cre+ or C.  WT femur.  All 
images at 20X. 
 
 
Another feature that distinguishes Nfatc1fl/∆ Ctsk-Cre+ mice from other osteoclast 
deficient mice is premature lethality.  Nfatc1fl/∆ Ctsk-Cre+ die at 17 days after birth 
for reasons that are still unclear.  Mice with a global deficiency in NFATc1 
deficient experience embryonic lethality due to cardiac valve defects (De la 
Pompa et al.  1998).  As cathepsin K is expressed in the endocardium (Lange 
and Yutzey 2006) we hypothesized that cathepsin K driven deletion of Nfatc1 in 
these mice may result in cardiac valve defects leading to premature death.  
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Histological analysis of the cardiac valves performed by our collaborator Dr. 
Yutzey, revealed that this was not the case (Figure 9).  Given the replacement of 
bone marrow hematopoietic elements noted above, and the lack of observed 
extramedullary hematopoiesis (data not shown), it is possible that Nfatc1fl/∆ Ctsk-
Cre+ mice die from bone marrow failure and anemia.  In fact, Nfatc1fl/∆ Ctsk-Cre+ 
are modestly anemic prior to death (not shown), and investigation of blood 
counts on the usual day of death are ongoing.  Alternatively, abnormal rib bones 
may lead to restrictive pulmonary physiology and Nfatc1fl/∆ Ctsk-Cre+ may die 
from respiratory compromise.  This possibility is currently being pursued. 
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Figure 9: Premature death in Nfatc1fl/∆ Ctsk-Cre+ Mice is not due to Cardiac 
Defect.  Heart valves in 4 wild-type mice (top) and 4 Nfatc1fl/∆ Ctsk-Cre+ mice 
(bottom).  Valve morphology appeared normal in both genotypes (images 
courtesy of Katherine Yutzey).  
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2. Origin of Marrow Fibrosis: Osteoblast? 
2.1. Loss of NFATc1 in Osteoblast-lineage cells does not cause Fibrosis 
Phenotype.   
One hypothesis that may explain the marrow fibrosis phenotype is that 
Cathepsin K expression in cells of the osteoblast or other mesenchymal/stromal 
cells results in NFATc1 deletion in the Nfatc1fl/∆ Ctsk-Cre+ mice, resulting in 
stromal cell intrinsic effects on proliferation or differentiation.  In fact, cathepsin K 
expression in osteocytes, cells of the osteoblast lineage, has been demonstrated 
(Bonewald 2011).  Thus, we tested the possibility that the marrow fibrosis is an 
osteoblast-lineage intrinsic phenotype by deleting NFATc1 in osteoblasts.  In 
prior work from the lab, an osteoblast specific promotor, osterix (Osx), was used 
to drive Cre-mediated deletion of NFATc1 and no gross differences bone 
morphology were observed in these mice (Figure 10).  Secondly, genotyping of 
stromal cells purified and cultured from Nfatc1fl/∆ Ctsk-Cre+ mice did not show 
deletion of the floxed allele.  These results substantiate the notion that the 
proliferation of stromal cells is more likely secondary to the deletion of NFATc1 in 
mature osteoclasts. 
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Figure 10: X-Ray Images of Nfatc1fl/fl Osx-Cre+ and Nfatc1fl/fl Osx-Cre- 
Femurs.  No significant differences femur length or morphology are observed in 
Nfatc1fl/fl Osx-Cre+ compared to Cre- wild-type littermates.(Taken from Aliprantis 
et al.  2008). 
 
As the stromal cell infiltrate in Nfatc1fl/∆ Ctsk-Cre+ mice occasionally 
demonstrated invasion into the hypertrophic chondrocyte zone(data not shown), 
we hypothesized that the stromal cell phenotype could arise from malignant 
transformation.  Thus, karyotyping was performed on stromal cells cultured from 
Nfatc1fl/∆ Ctsk-Cre+ bone.  No clonal abnormalities were evident (data not 
shown), arguing against malignant transformation arising in stromal cells of 
Nfatc1fl/∆ Ctsk-Cre+ mice. 
 
2.2. Osteoblast differentiation from Nfatc1fl/∆ Ctsk-Cre+ BMSC is normal 
Although we were unable to detect deletion of the floxed Nfatc1 allele by 
genotyping of Nfatc1fl/∆ Ctsk-Cre+ stromal cells, it remains possible that this 
genetic background results in stromal cell intrinsic defects in osteoblast 
differentiation.  Ctsk-Cre mediated deletion of NFATc1 in a minority of stromal 
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cells, below the threshold of detection by PCR genotyping, could inhibit the ability 
of the osteoblasts to differentiate, causing the progenitors to accumulate as a 
consequence.  To test this hypothesis, we sort purified CD45- non-hematopoietic 
cells from bone digests of Nfatc1fl/∆ Ctsk-Cre+ and WT littermate controls and 
expanded them in BMSC media.  Sort-purified BMSCs were cultured in 
osteoblast differentiation media for 21 days.  Osteoblast differentiation was 
assessed by staining for alkaline phosphatase (a marker of osteoblast 
differentiation) and by von kossa staining to assess formation of mineralized 
nodules (a marker of mature osteoblast function).  Alkaline phosphatase and von 
kossa staining at 7, 14, and 21 of differentiation showed no apparent differences 
between BMSCs isolated from WT mice and those isolated from Nfatc1fl/∆ Ctsk-
Cre+ mice  (Figure 11).  These results are representative of two independent 
experiments. 
Figure 11: Osteoblast Differentiation from WT and Nfatc1fl/∆ Ctsk-Cre+ BMSC 
is indistinguishable.  Osteoblast cultures stained for alkalkine phosphatase 
activity (blue) and for mineral deposition by von kossa staining (black) at 7, 14, 
and 21 days is shown.   
 
 In addition to the alkaline phosphatase and von kossa staining, we also 
performed quantitative real time PCR on these samples to measure the 
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expression of various known osteoblast markers during differentiation (Figure 
12).  We specifically measured the expression levels of tissue-nonspecific 
alkaline phosphatase (TNALP), runt related transcription factor 2 (Runx2), osterix 
(OSX), and osteocalcin (OCN) and normalized their expression to the 
housekeeping gene hypoxyxanthine guanine phosphoribosyl transferase 
(HPRT).  We found that expression levels of all the targets in the Nfatc1fl/∆ Ctsk-
Cre+ BMSCs matched and even surpassed the levels in WT BMSCs.  Altogether, 
this data suggests that there does not appear to be an intrinsic defect in the 
ability of Nfatc1fl/∆ Ctsk-Cre+ BMSCs to differentiate into osteoblasts.   
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Figure 12: Expression of Osteoblast Differentiation Markers on 
Differentiated WT vs Nfatc1fl/∆ Ctsk-Cre+ Sort Purified CD45- BMSCs.  
Quantitative RT-PCR was performed to measure expression levels of known 
osteoblast differentiation markers on samples of sort purified CD45- BMSCs that 
were in osteoblast differentiation media for either 0, 7, 14, or 21 days.  All 
expression levels were normalized to HPRT expression levels.   
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3. Marrow Fibrosis is Secondary to Loss of NFATc1 in Mature Osteoclasts 
3.1. RANK and Osteoclasts are Required for the Fibrosis Phenotype 
 Given that NFATc1 is activated by RANKL signaling (Takayanagi et al.  
2002), we hypothesized that RANK stimulation in the absence of NFATc1 in 
mature osteoclasts may lead to the production of a factor (which we will refer to 
as Factor X) that induces BMSC proliferation.  In the absence of RANK signaling 
then, and thus the absence of osteoclasts, Factor X will not be produced and the 
bone phenotype should look like that of Rankfl/fl Ctsk-Cre+ mice—the classic 
osteoclast-poor osteopetrosis with no stromal cell proliferation.  To test this 
hypothesis we generated osteoclast specific NFATc1 and RANK double 
knockouts to examine histologically.  We crossed Nfatc1fl/fl Ctsk-Cre+ mice to 
Rankfl/fl Ctsk-Cre mice to generate Nfatc1fl/fl Rankfl/fl Ctsk-Cre double mutant 
mice. 
To fully characterize the dependence of the NFATc1 phenotype on RANK, 
we also examined Nfatc1fl/∆ Ctsk-Cre+  heterozygous for RANK (Figure 13).  
Histological analyses of the femurs of P16 mice demonstrated that RANK 
heterozygosity did not rescue the Nfatc1fl/∆ Ctsk-Cre+ phenotype.  The mice still 
demonstrate the same phenotype: they are runted, toothless, have increased 
bone volume, and have the trademark proliferation of BMSCs in the marrow. 
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Figure 13: Rank Heterozygosity does not Rescue Nfatc1fl/∆ Ctsk-Cre+ 
Phenotype.  Images growth plate (left) and marrow (right) of femurs from P15 
mice.  A.  Wild-type control Nfatc1fl/+ Rankfl/+ Ctsk-Cre+.  B.  Nfatc1fl/∆ Rankfl/+ 
Ctsk-Cre+, and C.  Nfatc1fl/∆ Rank+/+ Ctsk-Cre+.  H&E, 5x (right panels) and 20x 
(left panels). 
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A total of approximately 130 pups were screened before a single 
osteoclast specific NFATc1/RANK double knockout was identified.  This number 
falls far below the expected mendelian ratio, suggesting the possibility of 
embryonic or early post-natal loss of these double knock-outs.  Saggital sections 
of the femurs of this P14 double-knockout and its littermates were stained for 
H&E (Figure 14).  As expected, the Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+, double 
osteoclast specific knockouts looked very similar to Rank fl/fl Ctsk-Cre+, exhibiting 
the classical osteoclast-poor osteopetrosis with normal hematopoietic marrow 
elements.  TRAP staining confirmed that Nfatc1fl/∆ RANK fl/fl Ctsk-Cre+, like RANK 
fl/fl Ctsk-Cre+, have an absence of TRAP-positive osteoclasts (Figure 14C). µCT 
analysis was performed and the bone phenotype of the Nfatc1fl/∆ RANK fl/fl Ctsk-
Cre+ was compared to a wild-type littermate and age matched single osteoclast-
specific knock outs (Figure 15).  The Nfatc1fl/∆ RANK fl/fl Ctsk-Cre double knock-
out was most similar to the RANK fl/fl Ctsk-Cre+.  Collectively, these data suggest 
that RANK signaling is required to for expression of this NFATc1 dependent 
phenotype, possibly because RANK signaling is required for osteoclast 
formation. 
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Figure 14: Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+ Double Mutants Resemble Rank fl/fl 
Ctsk-Cre+ Single Mutants Histologically.  H&E staining of femur growth plates 
of P14 mice shown at 5X, 10X and 20X magnifications (A&B).  A.  Wild-type 
control Nfatc1fl/+ Rankfl/+ Ctsk-Cre
+.  B.  Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+ double 
mutant with the classic osteoclast poor osteopetrosis.  Higher magnification 
reveals normal hematopoietic elements in the bone marrow.  C.  TRAP staining 
of the WT control reveals the presence of many TRAP positive osteoclasts (left) 
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while similar TRAP staining in Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+ Double Mutants 
revealed a complete absence of TRAP positive osteoclasts (right). 
 
Figure 15: Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+ Double Mutant Most Resembles Rank 
fl/fl Ctsk-Cre+ Single Mutant in µCT Imaging .  µCT scans of P15 femurs from 
(from left to right): Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+ double mutant, Nfatc1fl/+ Rank fl/+ 
Ctsk-Cre+ wild-type littermate, Nfatc1fl/∆ Ctsk-Cre+ single mutant, and Rank
 fl/fl 
Ctsk-Cre+ Single Mutant.   
 
  
 42 
3.2. Loss of  NFATc1 in Hematopoietic Stem Cells is Insufficient to 
Produce Marrow Fibrosis in Fetal Liver Chimeras 
BMSCs and osteoblasts are of mesenchymal origin while osteoclasts are 
of hematopoietic origin.  The results found in the previous section, along with the 
phenotype of the Nfatc1fl/∆ Rank fl/fl Ctsk-Cre+, suggest that osteoclasts, and thus 
hematopoietic cells, are required for expression of the phenotype.  To determine 
if hematopoietic cells are sufficient for expression of this proliferative stromal cell 
phenotype, we generated fetal liver chimeras.  Adult CD45.1 hosts were lethally 
irradiated to eliminate the hematopoietic cell pool.  Fetal liver cells, a rich source 
of hematopoetic progenitors, from either wild-type or Nfatc1fl/∆ Ctsk-Cre+ CD45.2 
donors were subsequently injected into the hosts to reconstitute the 
hematopoietic cell population.  If the reconstituted hematopoietic cell population 
induces the marrow fibrosis phenotype, then we would have strong evidence that 
loss of NFATc1 in hematopoietic cells is sufficient to produce the marrow fibrosis 
phenotype.  Mice were examined at 8 weeks, with a larger cohort planned to be 
analyzed 24 weeks post-transfer for differences in histology and µCT analyses.  
Flow cytometry was also performed on the spleens, bone marrow, and peripheral 
blood leukocytes to verify and quantify the chimerism.   
Flow cytometric analysis using antibody stains specific for CD45.1 (Host) 
and CD45.2 (Donor) revealed that at 8 weeks greater than 90% of cells in blood, 
spleen, and bone marrow were donor derived (data not shown).  At 8 weeks, 
µCT analysis showed that hosts receiving hematopoetic cells from Nfatc1fl/∆ Ctsk-
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Cre+ donor had a slightly increased ratio of bone volume fraction (BV/TV) and 
trabecular thickness (Tb.  Th.) compared with the host receiving WT cells (Figure 
16 A and B).  This result is consistent with poor osteoclast formation due to 
NFATc1 deletion.   
 
Figure 16: µCT analysis of Week 8 Chimeric Mice.  A.  µCT scans of the 
femurs of CD45.1 WT hosts 8 weeks after reconstitution of hematopoietic stem 
cell pool using CD45.2 fetal of the indicated genotypes.  B.  Calculated bone 
parameters. 
 
Histological analysis was performed on the femurs of these week 8 
chimeras (Figure 17).  Although the marrow elements appeared relatively normal 
(Figure 17 A&B), we observed the trademark abnormal, giant, multinucleated, 
TRAP-positive osteoclasts (Figure 17C) in the recipient of Nfatc1fl/∆ Ctsk-Cre+ 
donor cells, suggesting that the osteoclast specific phenotype is transferred as 
 44 
would be expected.  Although results from our 24 week post-transfer cohort are 
still outstanding, our initial results suggest that hematopoietic cells are not 
sufficient to produce the fibrosis phenotype in an adult.  If the 24 week results 
similarly do not demonstrate transfer of the phenotype, it is possible that the 
rapid bone turnover and high osteoclast activity seen in neonatal mice is required 
to drive the phenotype.  We thus plan to repeat these transfers on newborn mice 
where bone turnover is very high, to see if the phenotype can be transferred 
under these conditions.   
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Figure 17: Fetal liver chimeras do not develop the Nfatc1fl/∆ Ctsk-Cre+ 
phenotype at 8 weeks post transfer.  Femur histology on recipients of A.  
Nfatc1fl/∆ Ctsk-Cre+ fetal liver cells or B.  WT fetal liver cells revealed no 
significant differences in histology or morphology, H&E, 10x.  C, D.  40X TRAP 
stained sections show demonstrate large abnormal appearing osteoclasts in the 
recipients of Nfatc1fl/∆ Ctsk-Cre+ fetal liver.  E.  Osteoclasts in recipients of WT 
fetal liver are small and flat. 
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4. Identification of an Osteoclast Derived Osteoblastic Proliferative Factor. 
4.1. Osteoclast Conditioned Media treated BMSC Proliferation Assays 
The proliferative stromal cell seen in Nfatc1fl/∆ Ctsk-Cre+ mice was also 
previously noted in a different mouse model by Ohishi et al. Ohishi studied mice 
with constitutively activated parathyroid hormone (PTH) or parathyroid hormone 
related protein (PTHrP) receptor (Ohishi et al.  2009) andidentified an expansion 
of fibroblastoid cells in the bone marrow that was similar to the phenotype 
observed in our Nfatc1fl/∆ Ctsk-Cre+ mice.  Ohishi additionally found that 
elimination of osteoclasts altogether by administration OPG eliminated the 
marrow fibrosis, while simply limiting the activity and number of osteoclasts via 
bisphosphonates only resulted in a partial reduction of the marrow fibrosis 
(Ohishi et al.  2009).  This observation suggested that the marrow fibrosis was 
dependent on the presence osteoclasts in addition to their resorptive activity.  In 
other words, the osteoclasts themselves—more so than their resorptive activity—
are somehow signaling stromal cells to proliferate.  The notion that the 
osteoclasts are signaling the stromal cells or osteoblast precursors to proliferate, 
again, evokes the concept of coupling.  Characterizing this marrow fibrosis and 
its underlying causes would thus deepen our understanding of osteoclast-
osteoblast coupling mechanisms.   
Our studies of Nfatc1fl/∆ Ctsk-Cre+ osteoblast differentiation and the rescue 
of the fibrotic phenotype by RANK deficiency suggests that the stromal 
proliferation seen in Nfatc1fl/∆ Ctsk-Cre+  mice is a secondary effect of deletion of 
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NFATc1 in osteoclasts and not an osteoblast intrinsic phenotype.  We 
hypothesize that NFATc1 in osteoclasts negatively regulates an osteoblast-
lineage proliferative factor that functions in coupling.  In other words, osteoclasts 
produce a factor, which we refer to as Factor X, that stimulates osteoblast 
lineage cells to proliferate and that this factor is negatively regulated by NFATc1 
(Figure 18).   
 
Figure 18: Proposed Hypothesis on Osteoclast Production of an Osteoblast 
Lineage Proliferative Factor.  Deletion of NFATc1 in mature osteoclasts 
removes negative regulation normally imposed on the production or secretion of 
a factor that stimulates proliferation on osteoblast-lineage cells (figure courtesy of 
Antonios Aliprantis). 
 
We attempted to develop an assay to identify Factor X on osteoblast 
lineage cells.  We differentiated osteoclasts from either Nfatc1fl/∆ Ctsk-Cre+ or 
wild-type hematopoietic progenitors in-vitro and collected the media that they 
were cultured in.  We hypothesized that this media, which we called conditioned 
media, would contain factors that are secreted by the osteoclasts, including 
Factor X.  We then cultured BMSCs with varying concentrations of conditioned 
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media and assayed proliferation by serial AlamarBlue assays as a measure of 
cell number. 
Osteoclasts were generated from livers isolated from E13.5 or E15.5 
fetuses and remained in culture for 5-7 days, after which the media was collected 
and pooled according to genotype (WT and Nfatc1fl/∆ Ctsk-Cre+).  BMSCs were 
plated onto 96 well plates at densities of 1000 cells/well and were allowed to 
adhere overnight in normal BMSC media.  The BMSCs were subsequently 
changed into BMSC media with 75%, 50% or 25%, and 0% concentrations of the 
conditioned media from WT or Nfatc1fl/∆ Ctsk-Cre+ osteoclasts.  Proliferation was 
measured at several time points using AlamarBlue reagent and fluorescence 
spectrophotometry.  We found no significant differences in proliferation between 
BMSCs growing in either media at any of the concentrations (Figure 19).  To 
determine whether the initial plating density may have interfered and obscured 
any differences in proliferation, a similar assay was performed using an initial 
density of 200 cells per well.  Plating at this density also failed to show any 
significant differences in proliferation of BMSCs (Figure 19B). 
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Figure 19: Osteoclast Conditioned Media Treated BMSC Proliferation 
Assay.  BMSC proliferation, as measured by AlmarBlue, for BMSCs cultured in 
Nfatc1fl/∆ Ctsk-Cre+ osteoclast conditioned media and BMSCs cultured in WT 
osteoclast conditioned media at multiple concentrations over 192 hours.  A.  
BMSCs plated at initial density of 1000 cells/well.  B.  Lower initial plating density 
of 200 cells/well.   
 
 Hematopoietic contaminants from the BMSC isolation may have 
developed into osteoclasts upon introduction to RANKL and M-CSF rich 
conditioned media.  As a consequence, these contaminating osteoclasts may 
have produced factors that interfered with our results.  In order to minimize this 
confounding factor, a similar conditioned media proliferation assay was 
performed on BMSCs isolated from Nfatc1fl/∆ Ctsk-Cre+ mice.  The hematopoietic 
stem cells in these mice lose the ability to form osteoclasts and would thus 
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interfere minimally.  Similar proliferation experiments using these Nfatc1fl/∆ Ctsk-
Cre+ BMSCs still were unable to demonstrate significant differences in 
proliferation with treatment of the different conditioned media (Figure 20). 
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Figure 20: Osteoclast Conditioned Media Treated Nfatc1fl/∆ Ctsk-Cre+ BMSC 
Proliferation Assay.  BMSCs from Nfatc1fl/∆ Ctsk-Cre+ mice were treated in 
either Nfatc1fl/∆ Ctsk-Cre+ osteoclast conditioned media or WT osteoclast 
conditioned media and then assayed for proliferation using AlamarBlue over the 
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course of 144 hours.  No differences in proliferation were observed between the 
two treatment groups at any concentration.   
 
 The lack of significant differences in proliferation of BMSCs with treatment 
of either of the conditioned media may be due to a multitude of factors.  The 
presence of osteoclasts from the contaminating hematopoietic elements from the 
BMSC isolation may overwhelm any effect produced by the conditioned media.  
We plan to address this in future experiments by adding OPG to the BMSC 
cultures to inhibit the formation of osteoclasts.  Another possibility may be that 
the osteoclasts that we culture in-vitro are inherently different from the primary 
osteoclasts in vivo.  The osteoclasts in culture, for example, have a much shorter 
life-span than do the osteoclasts in vivo.  Methods for isolating primary 
osteoclasts, however, are highly limited at the moment and we are planning to 
further investigating this.  Co-culturing these osteoclasts with osteoblasts or with 
whole limbs to emulate in vivo conditions may yield better results.  Yet another 
possibility may be that proliferative factor is only released from osteoclasts after 
apoptosis (K. Matsuo and Irie 2008).  Further experimentation using different 
approaches to generate osteoclast conditioned media will be necessary to 
identify the factor which couples Nfatc1fl/∆ Ctsk-Cre+ osteoclasts to stromal cell 
proliferation. 
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4.2. Candidate coupling factors identified by Microarray Analysis of 
Nfatc1-deficient Osteoclasts 
The hyperproliferation of bone marrow stromal cells is unique feature of 
NFATc1 deficiency in mature osteoclasts.  Thus, we hypothesize that the 
putative coupling factor is regulated by NFATc1.  Utilizing existing microarray 
data comparing the transcriptome of osteoclasts generated from precursors 
lacking NFATc1 to WT osteoclasts, we identified genes upregulated in the 
absence of NFATc1 and reviewed their function to identify possible candidate 
proliferative factors.  In previous work from the lab, microarray transcriptional 
profiling was done on duplicate samples of bone marrow derived osteoclasts 
generated from polyI:C treated Nfatc1fl/fl MxCre+ mice, which lack NFATc1 in 
osteoclast precursors, and Nfatc1fl/fl MxCre- controls(Aliprantis et al.  2008; 
Charles et al.  2012).  Using this available data, we identified transcripts that 
were upregulated by at least two-fold in the absence of NFATc1.  This list was 
further reduced and condensed to reflect genes that either 1) were identified in 
the literature as being secreted, 2) have important functions in maintenance, 
proliferation, or differentiation of bone cells; or 3. were known to be critical to 
bone homeostasis.  Table 2 below summarizes candidate coupling factors 
identified by this approach, their expression levels in the Nfatc1fl/fl MxCre+ vs.  the 
Nfatc1fl/fl MxCre-, the false discovery rate (FDR), and their cellular location as 
listed by Mouse Genome Informatics (give website address).   
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Table 2: Upregulated Candidate Genes in NFATc1fl/fl MxCre+ vs. NFATc1fl/fl 
MxCre- Osteoclasts. Difference in expression is represented as a function of 
log2. 
Gene KO vs WT 
Expression 
Cellular Location 
Tgfb2 3.4462892 Extracellular Matrix, Extracellular 
Region, Secretory Granule 
Fgf13 2.2899338 Cytoplasm, growth cone, cell 
projection, 
Inhbb 2.2806169 Extracellular region, perinuclear 
region of cytoplasm. 
Tnfrsf22 2.24555 Extracellular region, integral to 
membrane 
Wif1 2.0259958 Extracellular 
Ndp 1.9958691 Extracellular, Extracellular Matrix 
 
 
4.2.1. A Description of Candidate Coupling Factors Identified by Microarray 
Analysis 
 
Transforming Growth Factor Beta-2 (Tgfb2) 
TGF-β is known to have an important role in the modulation of bone formation.  
Both TGF-β1 and β2 are variably expressed in bone.  The effects of TGF-β1 and 
TGF-β2 on cell death have been shown to also be highly variable.  In 
osteoblasts, TGF-β1 was shown to decrease activated apoptosis.  In bone-
marrow derived osteoprogenitor cells,however, TGF-β signaling was shown to 
promote apoptosis(Dufour, Holy, and Marie 2008).  Dufou, Holy, and Marie 
showed in their 2008 study that TGF-β2 prevents osteoblast apoptosis via 
Alpha5 Beta1-integrin, Pi3k/Akt signaling cascade and downstream Bcl-2 and 
phospho-Bad survival proteins.  These findings coupled with the highly variable 
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yet poorly understood nature of TGF- β on bone make Tgfb2 a feasible candidate 
in our search for a proliferative factor to explain Nfatc1fl/∆ Ctsk-Cre+ phenotype.   
Fibroblast Growth Factor 13 (FGF13) 
Though little is known about FGF13 other than its potential role in regulating 
functions of cells in the bulge and basal region of the epidermis (Kawano et al.  
2004), other members of the same FGF family have been found to have active 
roles in bone regulation.  Endogeneous FGF has been shown to control 
chondrogenesis and osteoblastogenesis via recruitment of chondroblasts and 
cells of osteoblast lineage to sites of endochondral bone formation (Miraoui and 
Marie 2010).  FGF2, specifically, has been demonstrated to create an increased 
pool of osteoprogenitors and has been found to be critically important in the 
anabolic effects of PTH on bone (Hurley et al.  2006).  Sabbieti et al.  has 
additionally shown that the exported FGF2 isoform is a critical determinant of 
bone mass via modulation of the Wnt signaling pathway (Sabbieti et al.  2009).  
While FGF13 itself does not appear to be secreted (Wu et al. 2012), another 
member of the FGF family, FGF18, was shown to be an essential autocrine 
positive regulator of the osteogenic differentiation program in murine 
mesenchymal stem cells (Hamidouche et al.  2010).  Knock-out studies of 
receptors for FGF have demonstrated a decrease in proliferation of 
osteoprogenitor cells in FGF-receptor deficient mice, a feature of direct relevance 
in our search for a proliferative factor in our Nfatc1fl/∆ Ctsk-Cre+ phenotype.  
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Further studies of the specific function of FGF13 and its relation to other family 
members may elucidate more about its potential role in bone homeostasis. 
 
Tumor Necrosis Factor Receptor Super Family 22 (Tnfrsf22) 
Tnfrsf22 appears to be a duplicated gene of Tnfrh1 that encodes decoy receptors 
of the tumor necrosis factor superfamily.  Being a member of the TNF 
superfamily suggests the possibility that Tnfrsf22 may have features similar or 
analogous to other members of the superfamily.  One of these features is the 
ability to bind TRAIL (Schneider et al.  2003), a ligand that has been implicated in 
causing the apoptosis of osteoblasts(Mori et al. 2009), and may thus have a role 
regulating the proliferation of osteoblast-lineage cells.  
 
Wnt Inhibitory Factor 1 (Wif1) 
Wif1 is one of three extracellular modulators of the Wnt signaling pathway 
identified so far.  The roles of these extracellular modulators appear to be 
negative (Han and Lin 2005).  The Wnt pathway has a crucial role in the pathway 
for the commitment of mesenchymal progenitors to the osteoblast lineage and for 
bone homeostasis (Galli et al.  2012).  The fact that Wif is a known extracellular 
modulator of the Wnt pathway, which is integral to bone homeostasis, makes 
Wif1 a candidate for further study. 
Norrie Disease Protein (NDP) 
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Studies on NDP have been quite limited.  Current literature has only elucidated 
the role of NDP as an essential player in retinal neuron development & capillary 
development in the brain & ear.  NDP is thought to act through the Wnt/B-
Catenin pathway (Braunger and Tamm 2012), however, and thus may have as 
yet undiscovered function in bone. 
 
4.2.2. Validation of Candidates by qRT-PCR 
We next verified that candidate NFATc1 regulated coupling factors 
identified above are also induced in mature osteoclasts lacking NFATc1, and 
thus are valid potential candidates for a coupling factor made by Nfatc1fl/∆ Ctsk-
Cre+ osteoclasts.  Using primers specific for the genes in Table 1, we examined 
expression levels of each candidate in Nfatc1fl/∆ Ctsk-Cre+ and wild type control 
osteoclast cultures by RT-PCR.   RNA was prepared from osteoclasts cultured 
from either Nfatc1fl/∆ Ctsk-Cre+ or WT fetal livers, n=3 for each genotype.  As an 
additional control, fetal liver derived Nfatc1fl/∆ Ctsk-Cre+ or WT macrophages 
were differentiated in the presence of MCSF.  To verify osteoclast differentiation 
and that Nfatc1 was deleted in the Nfatc1fl/∆ Ctsk-Cre+ cultures, we performed a 
RT-PCR using Calcitonin Receptor, a marker of mature osteoclasts, and primers 
to the floxed exon of Nfatc1.  We normalized all the expression levels relative to 
HPRT (Figure 21).  Although none of the candidates showed significant 
differences in expression between wild-type and Nfatc1fl/∆ Ctsk-Cre+ osteoclasts, 
the trend suggests that Tgfb2, Fgf13, and Tnfrsf22 are induced in the absence of 
Nfatc1 in mature osteoclasts.  We plan to repeat this experiment with additional 
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osteoclast cultures.  Once verified, we plan to purchase these factors in their 
active forms and design experiments to evaluate their effects on BMSC 
proliferation or differentiation. 
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Figure 21: Validation of Microarray Candidates using Quantitative RT-PCR.  
RT-PCR results showing: the expression of known osteoclast markers Calcitonin 
Receptor and NFATc1exon3, the expression of candidate genes TFGb2 
(Transforming Growth Factor-β2), FGF13 (Fibroblast Growth factor 13), Tnfrsf22 
(Tumor Necrosis Factor Receptor Super Family 22), and Inhbb (Inhibinbb).  
Samples included day 6 WT OC, Nfatc1fl/∆ Ctsk-Cre+ osteoclast (KO), WT 
Macrophages, and Nfatc1fl/∆ Ctsk-Cre+ Macrophages.  All expression values are 
normalized to HPRT.   
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Discussion 
We set out to characterize and elucidate an underlying mechanism of the 
unexpected phenotype of bone marrow effacement by stromal cell proliferation 
accompanied by giant abnormal osteoclasts observed in Nfatc1fl/∆ Ctsk-Cre+ 
mice.  While our understanding of this phenotype has been furthered on several 
fronts, many questions are left unanswered.  However, investigating the 
mechanism by which loss of NFATc1 in mature osteoclasts results in stromal cell 
proliferation may provide new insights into osteoclast-osteoblast cross talk.  .   
One of the striking features we have noted in the µCT scans of our 
Nfatc1fl/∆ Ctsk-Cre+ femurs is the absence of cortical bone.  This implies that 
there may be a role for osteoclasts in the initial formation of cortical bone, a 
process developmentally distinct from trabecular bone formation.  This is an 
intriguing possibility that warrants further study.   
The osteoblast –specific deletion of Nfatc1 provides evidence against the 
hypothesis that the fibrosis phenotype is of mesenchymal origin.  It must be 
noted, however, that Nfatc1 was deleted using Osterix-Cre.  Osterix is expressed 
late in the osteoblast lineage and deletion of Nfatc1 earlier in the osteoblast 
lineages may provide stronger evidence to dispute this hypothesis.  We are 
currently planning to use Prx1-Cre, one of the earliest possible osteoblast-
lineage specific promotors, to drive deletion of Nfatc1.   
The identification and characterization of the stromal cell infiltrate in 
Nfatc1fl/∆ Ctsk-Cre+ has proven to be a difficult task to accomplish.  We have, so 
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far, relied mainly on the morphology of these cells and their ability to differentiate 
into osteoblasts in vitro to identify these cells as osteoblast lineage cells.   
To verify that the marrow fibrosis phenotype is of hematopoietic origin, we 
attempted to see if the reconstitution of an adult WT mouse’s hematopoietic 
system with Nfatc1fl/∆ Ctsk-Cre+ HSC’s would also transfer the fibrotic phenotype.  
The failure for this to occur, as mentioned previously, may be due to the possible 
dependence of the fibrosis phenotype on a state of high bone turnover, which is 
not met in adult mice.  We plan to repeat the experiment on neonatal pups to see 
if the marrow fibrosis phenotype is indeed dependent on a state of high bone 
turnover.   
Failure of the conditioned media assays to demonstrate activity in BMSCs 
proliferation or differentiation assays may be due to a plethora of reasons.  
Based on the short lifespan of in vitro osteoclasts compared with in vivo 
osteoclasts, we believe that the in vitro conditions used in our experiments may 
not sufficiently represent the in vivo conditions.  We thus plan to address this by 
performing osteoclast and osteoblast co-cultures for conditioned media, or by 
using whole limb cultures to provide an environment rich in all the in-vivo factors.   
Microarray analysis is a powerful tool in comparing expression profiles and 
in pinpointing specific genes that are upregulated under a given condition.  Using 
results from the microarray analysis, we identified candidate coupling factors that 
were upregulated in osteoclasts in the absence of Nfatc1, were present in 
extracellular regions or on the membrane surface and that had functions that 
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may regulate proliferation, differentiation, or apoptosis of osteoblast-linage cells.  
We then verified that these genes are expressed in osteoclasts, and found trends 
toward increased expression in Nfatc1fl/∆ Ctsk-Cre+ for Tgfb2, Fgf13, and 
Tnfrsf22.  The microarray results analyzed to identify candidates in this paper 
were from in NFATc1fl/fl MxCre+ vs.  the NFATc1fl/fl MxCre- Osteoclasts.  We, 
however, are more interested in the expression profiles of mature osteoclasts—
the NFATc1fl/fl CtsKCre+ osteoclasts.  We thus have plans to perform a similar 
microarray analysis using RNA from Nfatc1fl/∆ Ctsk-Cre+ osteoclasts.  In parallel 
we plan to pursue the candidates listed in Table 1 by further examining whether 
they are upregulated in Nfatc1fl/∆ Ctsk-Cre+ and assaying their effects on BMSC 
proliferation or differentiation.  This last step is, of course, contingent on the 
availability of these factors in their active form.   
The bone marrow stromal cell proliferation seen in our Nfatc1fl/∆ Ctsk-Cre+ 
mice resembles the same fibrotic stroma seen in the bone marrows of human 
patients with fibrous dysplasia. These patients also manifest an effacement of 
hematopoietic elements in their bone marrow by hyperproliferating BMSCs 
(Riminucci et al. 1999).  Furthermore, fibrous dysplasia appears to be dependent 
on the presence of osteoclasts as treatment with denosumab, an antibody to 
RANKL, reduced the expansion of fibrous dysplasia dramatically (A. M. Boyce et 
al. 2012). The analogous features of fibrous dysplasia and the NFATc1fl/fl, 
CtskCre phenotype delineates a possible path for translational research.  
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We believe that the prospects for this project are promising.  Current 
understanding of osteoclast to osteoblast cross-talk is not very well developed 
and pursuit of a “coupling factor” is highly warranted given the potential 
implications finding such a factor would bring to our understanding of skeletal 
biology both in homeostasis and disease. Discovery of a “coupling” factor would 
not only deepen our understanding for bone remodeling, but would open up 
many avenues to understanding the pathogenesis of human skeletal diseases 
and possible therapeutic targets. 
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